View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
MONDAY, Sept. 27 (HealthDay News) -- Octapharma and the U.S. Food and Drug Administration have announced a voluntary market withdrawal of all lots of Immune Globulin Intravenous (human) 5 percent Liquid Preparation (Octagam) currently in the U.S. market, as the drug is potentially associated with an increased number of thromboembolic events.
Immune Globulin Intravenous (human) 5 percent Liquid Preparation is indicated for the treatment of primary humoral immunodeficiency, which includes congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
On Aug. 20, Octapharma withdrew 31 lots of the drug due to an increased number of thromboembolic events. There were nine thromboembolic events potentially associated with seven of those 31 lots. Octapharma, in collaboration with the FDA, developed advanced testing methodologies to determine the potential for a higher risk of thromboembolic events with intravenous immune globulin products. This testing raised concerns with 24 additional lots of the drug. While no additional thromboembolic events have been reported since that date, the company has now withdrawn all lots of the drug, as the root cause of these events has yet to be determined
According to an FDA safety alert, "customers are asked to immediately quarantine the use of affected lots and to contact Octapharma's Customer Service Department to arrange for product return."
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top